BioCentury
ARTICLE | Company News

ArQule, Kyowa Hakko Kogyo Co. Ltd. deal

April 30, 2007 7:00 AM UTC

ARQL granted Kyowa Hakko exclusive rights to develop and commercialize ARQ 197 to treat solid tumors in Japan, China, South Korea and Taiwan. ARQL will receive $30 million up front and is eligible fo...